Low prevalence and disease severity of COVID-19 in post-liver transplant recipients—A single centre experience

Anita Verma | Shirin Elizabeth Khorsandi | Annalisa Dolcet | Andreas Prachalias | Abid Suddle | Nigel Heaton | Wayel Jassem

Institute of Liver Studies, King's College Hospital, London, UK

Correspondence
Wayel Jassem, Institute of Liver Studies, King's College Hospital, Denmark Hill, London SE5 9RS UK.
Email: wayel.jassem@kcl.ac.uk

Handling Editor: Jian Sun

BRIEF DEFINITIVE REPORT

Coronavirus disease 2019 (COVID-19) caused by a novel coronavirus called severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is driving a present day global pandemic. Immunosuppressed patients are regarded as a high-risk cohort. The following is a short report on COVID-19 in liver transplant recipients (n = 5) from a high volume UK liver transplant unit with a large follow-up cohort (n = 4500). Based on this limited data, liver transplant recipients appear to have a low incidence of COVID-19, with less severe symptoms than expected, when compared with the general population and other solid organ recipients. This possibly could be related to self-isolation adherence and/or the ‘ideal’ level of immunosuppression that favourably modulates the immune response to COVID-19.

KEYWORDS
COVID-19, immunosuppression, liver transplant

1 | INTRODUCTION

Coronavirus disease 2019 (COVID-19), a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first identified in December 2019, was declared a global pandemic by the World Health Organization in March 2020. The present pandemic has spread quickly, with an exponential growth in new cases and a worldwide mortality rate of 2%-10%. Measures imposed in many countries, including the UK have helped to reduce the number of new patients for health systems to cope.

Managing patients with COVID-19 is currently a major challenge in many countries, as the pathophysiology of COVID-19 is not fully understood and the treatment, is mainly supportive as evidence for specific therapies is yet to be established. The host immune response as determined by the innate and adaptive systems appears to be both the determinant of COVID-19 resolution, as well as the severity of the inflammatory response that results in SARS and death. As a consequence, immunocompromised individuals have been classified as a COVID-19 high-risk group. However, emerging data suggest that liver transplant recipients (adult and paediatric) may not necessarily be at increased risk, leading to the speculation that immunosuppression (IS) may paradoxically play a protective role, by modulating the immune host response to COVID-19.

Abbreviations: ALF, acute liver failure; BMI, body mass index; CA, community acquired; CNI, calcineurin inhibitor; COVID-19, coronavirus disease 2019; CPAP, continuous positive airway pressure; CXR, chest X-ray; FAP, familial amyloid polyneuropathy; HA, hospital acquired; IS, immunosuppression; MMF, mycophenolate mofetil; PCR, polymerase chain reaction; PFIC3, primary familial intrahepatic cholestasis type 3; PHE, Public Health England; PSC, primary sclerosing cholangitis; PTC, percutaneous transhepatic cholangiogram; RNA, ribonucleic acid; SARS-CoV-2, severe acute respiratory syndrome coronavirus-2; T2DM, type 2 diabetes mellitus; UC, ulcerative colitis; US, ultrasound; VOD, veno-occlusive disease; WHO, World Health Organization.

Anita Verma and Shirin Elizabeth Khorsandi are co-first authors.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2020 The Authors. Liver International published by John Wiley & Sons Ltd
The present report is a summary of our experience of COVID-19 in post-liver transplant recipients.

## CASES

Our Unit follows up nearly 4500 post-liver transplant patients, of which 25% were transplanted as children. To date, only five adult patients have been identified as having COVID-19 and none have died (see Tables 1 and 2 for demographic and clinical data summary). Two of these patients are awaiting re-transplantation (patient 1 + 2). Patient 1 is a slim man of 36 years with no significant co-morbidity who was originally transplanted for familial amyloid polyneuropathy in 2011. Development of a diffuse cholangiopathy led to him being relisted for redo liver transplant. He had been admitted for resiting of a blocked percutaneous transhepatic cholangiogram drain and during the admission developed a cough and low-grade fever. He was found to be SARS-CoV-2 RNA PCR positive on Day 15 of his inpatient stay, with chest X-ray (CXR) demonstrating some consolidation. Otherwise, he had reasonable graft function, but was lymphopenic from hypersplenism. No changes were made in his maintenance IS which was a low-dose calcineurin inhibitor (CNI). He was managed conservatively and discharged for self isolation. Presently, he is suspended from the transplant waiting list until 2 nasopharyngeal swabs are SARS-CoV-2 RNA PCR negative.

In the remaining patients, three did not have typical COVID respiratory symptoms. Patient 3 (54 years, male) was 6 years post his second transplant for primary sclerosing cholangitis (PSC). He had no significant comorbidity apart from a high body mass index (BMI) and a longstanding end ileostomy for management of his ulcerative colitis. He presented with headache, vomiting, photophobia and fever, leading to the admitting differential diagnosis of meningitis vs COVID-19. Lumbar puncture and CT head were normal, CXR was clear, but he was found to be SARS-CoV-2 RNA PCR positive. He was discharged after 3 days to continue with self isolation and no changes were made in his maintenance IS of CNI, azathioprine and prednisone. In Patient 4 (23 years, male), the presenting symptoms were of chest wall pain and fever. Their background history was of

### TABLE 1
Liver transplant recipients with COVID-19 demographic, comorbidities and underlying liver disease. Data summary for individual patient (pt), including age in years (y), sex (male: M or female: F), race, body mass index (BMI), date of liver transplant (LT), indication for primary LT and for redo or for relisting

| Pt | Age (y) | Sex | Race | BMI | Date LT (s) | Indication LT/relisting/redoLT | Comorbidity | In-patient stay (d) | Admission reason |
|----|---------|-----|------|-----|-------------|-------------------------------|-------------|---------------------|-----------------|
| 1a | 36      | M   | Cypriot | 18  | 2011        | Familial amyloid polyneuropathy/cholangiopathy | Nil         | 25                  | Blocked PTC     |
| 2a | 54      | M   | British | 30.9| 2004        | Chronic Budd Chiari/small vessel VOD, ascites | T2DM, hypertension, high cholesterol | 21                  | Cough, pyrexia  |
| 3  | 54      | M   | British | 27.9| 2009/2014   | Primary sclerosing cholangitis/primary sclerosing cholangitis | UC + ileostomy | 4                   | Headache, vomiting, photophobia, pyrexia |
| 4  | 23      | M   | British | 24.4| 2017/24/19  | Autosomal recessive polycystic kidney disease and congenital hepatic fibrosis/ductopenic rejection/antibody-mediated rejection | Nil         | 7                   | Chest wall pain and fever |
| 5  | 28      | M   | British | 21.4| 1998/20/20  | PFIC3/ALF | Nil         | 75                  | ALF second to variceal bleed |

Abbreviations: ALF, acute liver failure; PFIC3, primary familial intra-hepatic cholestasis type 3; PTC, percutaneous transhepatic cholangiogram; T2DM, type 2 diabetes mellitus; UC, ulcerative colitis; VOD, veno-occlusive disease.

Marks patients who are relisted.

### Key points
Liver transplant recipients appear to have a low incidence of COVID-19, with less severe symptoms, when compared with the general population and other solid organ recipients.
**TABLE 2**  COVID-19 presentation, findings and outcome in liver transplant recipients. Summary of clinical data for each individual case

| Pt | CA or HA | COVID 19 symptoms | Chest X-ray | COVID 19 management | Other infections | WBC $\times 10^9$/L | Lymphocyte/neutrophil $\times 10^9$/L | IS regimen | Liver function tests | GFR mL/min |
|----|----------|------------------|-------------|---------------------|----------------|---------------------|---------------------------------|-------------|----------------------|------------|
| 1  | HA       | Low-grade fever, cough | Left basal consolidation | Isolation No change in IS Discharged | No | 0.66 | 0.26/0.33 | CNI | Tac 3.5 | Alb 30 Bil 57 INR 1.47 AST 64 | >90        |
| 2  | CA       | Cough, fever | Consolidation RLL + ML | AEs, CPAP 3/7, MMF stopped, pred dose doubled Inpatient | No | 3 | NA | MMF + Pred | MMF 0.6 | Alb 25 Bil 25 INR 1 AST NA | 66        |
| 3  | CA       | No respiratory symptoms | Nil | Isolation No change IS Discharged | No | 10.27 | 0.8/3.88 | CNI + Pred Azathoprine | Tac 2.8 | Alb 24 Bil 6 INR 1.17 AST 30 | 59        |
| 4  | CA       | No respiratory symptoms | Nil | Isolation No change IS Discharged | CMV | 5.22 | 0.66/3.46 | CNI + Pred (Alemtuzumab induction 3rd transplant) | Tac 3.2 | Alb 42 Bil 7 INR 1.07 AST 17 | 13        |
| 5  | HA       | No respiratory symptoms | Ground glass changes (longstanding) | No change in IS, started on remdesivir Inpatient | CMV, pulmonary IA | 1.78 | 0.71/0.86 | CNI + Pred | Tac 6.6 | Alb 27 Bil 9 INR 1.03 AST 16 | 63        |

Abbreviations: AEs, antibiotics; Alb, albumin, normal range 35–50 g/L; AST, aspartate aminotransferase, normal range 10–50 IU/L; Bil, bilirubin, normal range 3–20 $\mu$mol/L; CA, community acquired; CMV, cytomegalovirus; CNI, calcineurin inhibitor; CPAP, continuous positive airway pressure; GFR, glomerular filtration rate; GGT, gamma glutamyl transferase, normal range 1–55 IU/L; HA, hospital acquired; IA, invasive aspergillosis; INR, international normalized ratio, normal range 0.9–1.2 ratio; IS, immunosuppression; ML, middle lobe; MMF, mycophenolate mofetil; NA, not available; pred, prednisone; RLL, right lower lobe; tac, tacrolimus; WBC, white blood cell, normal range 4–11 $\times 10^9$/L, lymphocyte normal range 1.3–4 $\times 10^9$/L, neutrophil normal range 2.2–6.3 $\times 10^9$/L.
autosomal recessive polycystic kidney disease and congenital hepatic fibrosis requiring combined liver kidney transplant in 2017, then redo liver transplant in January 2019 for ductopenic rejection and October 2019 for antibody mediated rejection. For his third transplant he received Alemtuzumab induction. On admission, he had ultrasound drainage of a subphrenic collection and excision of a chest wall lesion that grew Rhizopus oryzae and Cryptococcus diffluens, so was treated with antifungals. In addition, his ECG had characteristic features for pericarditis. Initial nasopharyngeal swabs for SARS-CoV-2 RNA PCR were negative but on repeat, after a 7-day inpatient stay became positive. He clinically improved and had no respiratory concerns, so was discharged home, with no change in his maintenance IS of a CNI and prednisone. In contrast, Patient 5 (28 years, male) was an inpatient when found to be SARS-CoV-2 RNA PCR positive. He had originally been transplanted as a child for primary familial intrahepatic cholestasis type 3 and required emergency retransplantation (February 2020) following a catastrophic bleed that induced acute liver failure in an already failing graft. He was recovering from a critical illness myopathy and was on dual antifungals for pulmonary aspergillosis. A date for discharge was planned but he started to complain of chills and throat pain, leading to COVID-19 testing that was found to be positive on Day 67 of his admission. In view of his history and ongoing treatment for aspergillosis, he was recruited into a COVID trial and randomized to receive remdesivir (200 mg IV day 1 followed by 100 mg day 2-5). His IS remains CNI based with the dose presently being titrated according to trough. He currently remains an inpatient, but is clinically well.

3 | DISCUSSION

Since the outbreak of the coronavirus pandemic, the apparent incidence of COVID-19 among our post-liver transplant patients has been relatively low at 0.1% in comparison to the general population of 0.3% in the UK and 0.4% in the USA. All of our confirmed cases have presented with mild symptoms that have improved with routine supportive therapy, none have required invasive ventilatory support and none have died. All are adult males and severity of symptoms associated with a comorbidity profile of obesity and metabolic syndrome (hypertension, hypercholesterolaemia and diabetes). Reflecting the reported demographics of the typical COVID-19 patient, their risk of death, with apparent sparing of children. In contrast, COVID-19 death rates post-kidney transplant are widely reported to be >25%.

The fact that transplant recipients in the UK have been classified as very high risk (also called extremely vulnerable) for COVID-19 by Public Health England (PHE) and have been in strict self-isolation from the start of the UK lock down that started on the 23 March 2020 could on its own explain the reduced incidence of COVID-19. Similar, observations and comments have come from both Italy and Spain. In the UK, testing for COVID-19 is currently offered to symptomatic patients or recipients about to be discharged into the community (PHE guidelines version 32 updated 23 April 2020). Therefore, the true number of positive, asymptomatic recipients presently remains unknown and could be higher than the general population, if IS therapy is truly playing a ‘protective’ role in attenuating COVID-19 symptoms. Of note, liver transplant recipients and other solid organ recipients with COVID-19-related symptoms in the UK have a low threshold to ensuring that their implanting unit is aware of their clinical status. So, in terms of ‘symptomatic’ COVID-19 in the present liver transplant cohort, whether that be from the community or inpatient in their local hospital, we believe the data, despite its limitations, to be representative.

Most of the recipients in the present series presented with mild symptoms, requiring minimal supportive management and limited changes in their maintenance IS. These mild symptoms at presentation could be related to IS modulating the immune response against COVID-19 in a beneficial manner. Reports by Carbajo-Lozoya 2012 and Tanaka 2013 have demonstrated that CNIs such as cyclosporine and tacrolimus can reduce the viral load by inhibiting viral replication though the suppression of immunophilin pathways. Although, these observations are yet to be confirmed in a clinical setting, it is possible to hypothesize that CNIs by reducing the viral load are able to reduce the systemic inflammatory response and subsequent development of florid SARS.

There is also emerging evidence that the severe forms of SARS resulting in death are associated with an enhanced inflammatory response and cytokine storm. As a consequence, a number of clinical trials initiated for COVID-19 are targeting the immune response, such as tocilizumab, a monoclonal antibody directed against interleukin-6 to reduce cytokine levels. In a pilot study on 21 Chinese patients with severe COVID-19 pneumonia, tocilizumab was reported to improve lung function and has also been demonstrated to be of benefit, in a renal transplant patient with COVID-19. Ongoing randomized control trials will substantiate these observations. None the less, these preliminary observations are supportive of the view that IS may have a beneficial role in COVID-19 management, rather than per se increase the risk of COVID-19 pneumonia and death. However, the reported COVID-19 deaths in post-liver transplant patients to date (n = 3), had low levels of IS but all had underlying comorbidities.

In order to understand the role of IS/immune modulation in the context of COVID-19 management, more good quality data adjusted for established COVID-19 risk factors (eg BMI, age, gender, ethnicity, co-morbidity) from the different solid organ recipient groups is needed. By undertaking such an analysis, will establish whether high levels of IS combined with lymphocyte depletion, is allowing a high viral load to become the main driver of the inflammatory response. Thereby, explaining the observation that renal transplant recipients appear more vulnerable to COVID-19 than liver transplant recipients.

Fortunately, in the present series, the SARS-CoV-2 RNA PCR-positive liver transplant recipients have had in the most part mild symptoms that have not needed aggressive changes in management. For patients with mild self-limiting symptoms we have not made any changes in IS. However, if there is clinical concern, our IS strategy is withdrawal of anti-proliferative agents (ie azathioprine, MMF) and to maintain low levels of CNIs and if need be, increase the dose of steroids. Otherwise, standard of care is as for other COVID-19 patients, that is supportive or a given therapy within a context of a clinical trial.
In general, patients with COVID-19 present with symptoms of viral pneumonia such as dry cough, fatigue, headache and high temperature that in the second week of infection can rapidly progress to respiratory failure. But, COVID-19 like other viral infections can underlie atypical presentations which are of note in the immunosuppressed. In the present series, a number of the liver transplant recipients had atypical symptoms, such as photophobia, headache and chest pain which is in contrast to previous reports. Atypical presentations of COVID-19 have also been reported in elderly frail patients and in other solid organ transplant recipients. Highlighting, that in the present era constant vigilance is needed to minimize the spread of COVID-19 in the healthcare environment between patients and healthcare providers.

In conclusion, liver transplant recipients appear to have a low incidence of COVID-19, with less severe symptoms than expected compared to the general population and other solid organ recipients, possibly related to self-isolation adherence and/or level of immune response suppression to COVID-19.

CONFLICT OF INTEREST
None of the authors have any conflict of interest to declare.

ORCID
Shirin Elizabeth Khorsandi https://orcid.org/0000-0003-1624-4467

REFERENCES
1. WHO. Coronavirus disease 2019 (COVID-19) situation report – 52. March 12, 2020. https://www.who.int/docs/default-source/coronaviruse/20200312-sitrep-52-covid-19.pdf?sfvrsn=e2bfc9c0_2. Accessed March 13, 2020
2. Ahn C, Amer H, Anglicheau D, et al. Global transplantation COVID report march 2020. Transplantation. 2020. https://doi.org/10.1097/TP.0000000000003258
3. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506.
4. Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: a review. Clin Immunol. 2020;20:108427.
5. D’Antiga L. Coronavirus and immunosuppressed patients: the facts during the third epidemic. Liver Transpl. 2020;26:832-834.
6. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708-1720.
7. Zheng K, Gao F, Wang XB, et al. Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease. Metabolism. 2020;19:154244.
8. Tanaka Y, Sato Y, Sasaki T. Suppression of coronavirus replication by cyclophilin inhibitors. Viruses. 2013;5(5):1250-1260.
9. Carbajo-Lozoya J, Müller MA, Kallies S, Thiel V, Drosten C, von Brunn A. Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506. Virus Res. 2012;165(1):112-117.
10. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-1034.
11. Xiaoling XU, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA. 2020;117:10970-10975.
12. Fontana F, Alfano G, Mori G, et al. COVID-19 pneumonia in a kidney transplant recipient successfully treated with tocilizumab and hydroxychloroquine. Am J Transplant. 2020. https://doi.org/10.1111/ajt.15935
13. Bhooi S, Rossi RE, Citterio D, Mazzaferro V. COVID-19 in long-term liver transplant patients: preliminary experience from an Italian transplant centre in Lombardy. Lancet Gastroenterol Hepatol. 2020;5(6):532-533.
14. UK COVID-19 cases in wait list and organ transplant patients. https://www.arcgis.com/home/webmap/viewer.html?webmap=8721e647799940a8ac447c53cc1eb889&extent=-16.4563,49.9633,10.3943,57.2178. Accessed April 23, 2020.
15. Guillen E, Pineiro GJ, Revuelta I, et al. Case report of COVID-19 in a kidney transplant recipient: does immunosuppression alter the clinical presentation? Am J Transplant. 2020. https://doi.org/10.1111/ajt.15874
16. Tay HS, Harwood R. Atypical presentation of COVID-19 in a frail older person. Age Ageing. 2020. https://doi.org/10.1093/ageing/afaa068

How to cite this article: Verma A, Khorsandi SE, Dolcet A, et al. Low prevalence and disease severity of COVID-19 in post-liver transplant recipients—A single centre experience. Liver Int. 2020;40:1972-1976. https://doi.org/10.1111/liv.14552